KCa3.1: Target and marker for cancer, autoimmune disorder and vascular inflammation?

Expert Review of Molecular Diagnostics

Volumn 8, Issue 2, 2008, Pages 179-187

  Chou, Chuan Chu ^a   Lunn, Charles A ^a   Murgolo, Nicholas J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Autoimmune disorder; Cancer; Potassium ion channel; Vascular inflammation

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; CLOTRIMAZOLE; GEMCITABINE; KCA3.1 PROTEIN; MESSENGER RNA; POTASSIUM CHANNEL BLOCKING AGENT; TRAM 34; TUMOR MARKER; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NONHUMAN; PANCREAS CARCINOMA; REVIEW; TREATMENT WITHDRAWAL; TUMOR GROWTH; UPREGULATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MITOGENS; MUSCLE, SMOOTH, VASCULAR; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULITIS;

EID: 41549129593     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.2.179     Document Type: Review

References (63)

1. Fanger CM, Ghanshani S, Logsdon NJ et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J. Biol. Chem. 274, 5746-5754 (1999).
2. Wulff H, Kolski-Andreaco A, Sankaranarayanan A et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr. Med. Chem. 14, 1437-1457 (2007). •• Comprehensive review of small-compound and peptide blockers of KCa3.1.
3. Ishii TM, Silvia C, Hirschberg B et al. A human intermediate conductance calcium-activated potassium channel. Proc. Natl Acad. Sci. USA 94, 11651-11656 (1997).
4. Logsdon NJ, Kang J, Togo JA et al. A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J. Biol. Chem. 272, 32723-32736 (1997).
5. + channels inhibits progression of human endometrial cancer. Oncogene 26, 5107-5114 (2007).
6. 2+-activated potassium channel Kcnn4. J. Biol. Chem. 279, 47681-47687 (2004).
7. Burgess MA, Bodey GP. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob. Agents Chemother. 2, 423-426 (1972).
8. Wojtulewski JA, Gow PJ, Walter J et al. Clotrimazole in rheumatoid arthritis. Ann. Rheum. Dis. 39, 469-472 (1980).
9. + channels by cytochrome P-450 inhibitors. J. Biol. Chem. 267, 11789-11793 (1992).
10. Benzaquen LR, Brugnara C, Byers HR et al. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med. 1, 534-540 (1995).
11. + channel, IKCa1: a potential immunosuppressant. Proc. Natl Acad. Sci. USA 97, 8151-8156 (2000). • Properties of TRAM-34.
12. Stocker JW, De Franceschi L, McNaughton-Smith GA et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 101, 2412-2418 (2003). • Properties of ICA-17043.
13. Spear K. Novel tritylamides as potent, selective blockers of the Gardos potassium ion channel. Presented at: Strategic Research Institute Conference on Ion Channels in Drug Discovery and Development. Philadelphia, PA, USA, 20-21 May (2002).
14. + channels in mouse submandibular glands. J. Physiol. 581(Pt 2), 801-817 (2007).
15. Nakamoto T, Srivastava A, Romanenko VG et al. Functional and molecular characterization of the fluid secretion mechanism in human parotid acinar cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R2380-R2390 (2007).
16. + channel Kcnn4. J. Physiol. 583(Pt 2), 705-717 (2007).
17. + channel. Circ. Res. 99, 537-544 (2006).
18. Ataga KI, Orringer EP, Styles L et al. Doseescalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 26, 1557-1564 (2006). • Evidence of safety in treating human volunteers with a KCa3.1-blocking agent.
19. + channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery. J. Physiol. 553(Pt 1), 183-189 (2003).
20. Gillham JC, Myers JE, Baker PN et al. Regulation of endothelial-dependent relaxation in human systemic arteries by SKCa and IKCa channels. Reprod. Sci. 14, 43-50 (2007).
21. Felipe A, Vicente R, Villalonga N et al. Potassium channels: new targets in cancer therapy. Cancer Detect. Prev. 30, 375-385 (2006).
22. + channel in glioblastoma GL-15 cells. Cell Physiol. Biochem. 18, 47-56 (2006).
23. + channels inhibit human pancreatic cancer cell growth in vitro. Mol. Pharmacol. 65, 630-638 (2004).
24. + channels in breast cancer cells: association with cell cycle progression. Am. J. Physiol. Cell. Physiol. 287, C125-C134 (2004).
25. + channel modulators on human prostate cancer cell proliferation. Eur. J. Pharmacol. 471, 157-164 (2003).
26. + channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1á and the von Hippel-Lindau protein. J. Physiol. 571(Pt 2), 349-359 (2006).
27. + channel-dependent migration of fibroblasts and human melanoma cells. Cell. Physiol. Biochem. 9, 126-132 (1999).
28. Chou CC. Blocking ion channel KCNN4 alleviates inflammation symptoms by arresting the synthesis of key proinflammatory factors. Presented at: International Business Communications Conference on Assays and Cellular Targets. Bellevue, WA, USA 17-19 October (2005).
29. Khalid MH, Shibata S, Hiura T. Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J. Neurosurg. 90, 918-927 (1999).
30. Reich EP, Cui L, Yang L et al. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur. J. Immunol. 35, 1027-1036 (2005).
31. + channels in human mesenteric artery. A single-cell reverse transcriptase-polymerase chain reaction in situ. Circ. Res. 87, 496-503 (2000).
32. Takahashi H, Abe M, Sugawara T et al. Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis. Jpn. J. Cancer Res. 89, 445-451 (1998).
33. + channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 25, 704-770 (2005).
34. + channels regulate human airway smooth muscle proliferation. Am. J. Respir. Cell Mol. Biol 37, 525-531 (2007).
35. Mross K. Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. Drug Resist. Updat. 3, 223-235 (2000).
36. Ghanshani S, Wulff H, Miller MJ. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. 275, 37137-37149 (2000).
37. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 173, 776-786 (2004).
38. 2+ and membrane potential and promotes transcription of IL-6 in macrophages. Proc. Natl Acad. Sci. USA 101, 9479-9484 (2004).
39. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111, 1703-1713 (2003).
40. + channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25, 280-289 (2004).
41. Heber-Katz E. The ups and downs of EAE. Int. Rev. Immunol. 9, 277-285 (1993).
42. Khachigian LM. Collagen antibody-induced arthritis. Nat. Protoc. 1, 2512-2516 (2006)
43. + channels in human B lymphocytes and rat thymocytes. J. Physiol. (Lond.) 415, 69-83 (1989)
44. Moritoki Y, Lian ZX, Wulff H. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 45, 314-322 (2007)
45. Engel P, Tedder TF. New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens. Leuk. Lymphoma 13(Suppl. 1), 61-64 (1994).
46. Jonasson L, Holm J, Skalli O et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6, 131-138 (1986).
47. Toyama K, Saito T, Fujiwara Y et al. Intermediate conductance calcium-activated potassium channel, KCa3.1, plays an important role in macrophage (MØ) migration in atherosclerosis. FASEB J. 21, 743.18 (2007) (Abstract).
48. + channel (IKCa1) mediates phenotypic modulation of coronary smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 291, H2493-H2503 (2006).
49. Köhler R, Wulff H, Eichler I et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 108, 1119-1125 (2003).
50. Mauler F, Hinz V, Horvath E et al. Selective intermediate-/small- conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma. Eur. J. Neurosci. 20, 1761-1768 (2004).
51. Joiner WJ, Wang LY, Tang MD et al. hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Natl Acad. Sci. USA 94, 11013-11018 (1997).
52. + channels are required for human lung mast cell migration. Thorax 61, 880-885 (2006).
53. Olsson N, Ulfgren AK, Nilsson G. Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann. Rheum. Dis. 60, 187-193 (2001).
54. Soucek L, Lawlor ER, Soto D et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13, 1211-1218 (2007).
55. Whiteaker KL, Gopalakrishnan SM, Groebe D et al. Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators. J. Biomol. Screen. 6, 305-312 (2001).
56. Baxter DF, Kirk M, Garcia AF et al. A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J. Biomol. Screen. 7, 79-85 (2002).
57. + channels. J. Biomol. Screen. 12, 50-60 (2007).
58. Zhou BY, Ma W, Huang XY. Specific antibodies to the external vestibule of voltage-gated potassium channels block current. J. Gen. Physiol. 111, 555-563 (1998). •• Milestone work in proving the feasibility of targeting ion channels with blocking antibodies.
59. Rauer H, Pennington M, Cahalan M et al. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem. 274, 21885-21892 (1999).
60. Xu SZ, Zeng F, Lei M et al. Generation of functional ion-channel tools by E3 targeting. Nat. Biotechnol. 23, 1289-1293 (2005).
61. Wulff H, Chandy G, Miura H: WO/2007/033307 (2007).
62. Wulff H. TRAM-34, a potential new drug for transplant rejection and stroke. Abstract of Ion Channel Retreat 2007 - Overview, Aurora Biomed Inc. www.aurorabiomed.com/download/retreat%20ppt/Heike%20Wulff.pdf
63. Icagen News Release, April 3, 2007 http://ir.icagen.com/phoenix.zhtml?c= 178443&p=irol-newsArticle_Print&ID=981557&highlight